These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 27635937)

  • 1. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
    Barillà F; Pelliccia F; Borzi M; Camici P; Cas LD; Di Biase M; Indolfi C; Mercuro G; Montemurro V; Padeletti L; Filardi PP; Vizza CD; Romeo F;
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18(1):1-9. PubMed ID: 27635937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Tada T; King LA; Kastrati A
    Eur Heart J; 2012 Dec; 33(24):3078-87. PubMed ID: 23091199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
    Basaraba JE; Barry AR
    Am J Health Syst Pharm; 2016 May; 73(9):e229-37. PubMed ID: 27099329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence.
    Palmerini T; Stone GW
    Eur Heart J; 2016 Jan; 37(4):353-64. PubMed ID: 26795933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
    Navarese EP; Andreotti F; Schulze V; Kołodziejczak M; Buffon A; Brouwer M; Costa F; Kowalewski M; Parati G; Lip GY; Kelm M; Valgimigli M
    BMJ; 2015 Apr; 350():h1618. PubMed ID: 25883067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    Garg P; Galper BZ; Cohen DJ; Yeh RW; Mauri L
    Am Heart J; 2015 Feb; 169(2):222-233.e5. PubMed ID: 25641531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.
    Cho MS; Park DW
    Korean J Intern Med; 2017 Sep; 32(5):769-779. PubMed ID: 28823143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
    Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
    Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
    Zocca P; van der Heijden LC; Kok MM; Löwik MM; Hartmann M; Stoel MG; Louwerenburg JW; de Man FHAF; Linssen GCM; Knottnerus IL; Doggen CJM; van Houwelingen KG; von Birgelen C
    EuroIntervention; 2017 Nov; 13(10):1168-1176. PubMed ID: 29151439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
    Dobesh PP; Finks SW; Trujillo TC
    Clin Ther; 2020 Oct; 42(10):2084-2097. PubMed ID: 32873416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding versus thrombosis: role of short DAPT in complex lesions.
    Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
    Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ndrepepa G; Schunkert H; Fusaro M; Kastrati A
    Clin Res Cardiol; 2015 Oct; 104(10):887-901. PubMed ID: 25903112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
    Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
    Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
    Giustino G; Baber U; Sartori S; Mehran R; Mastoris I; Kini AS; Sharma SK; Pocock SJ; Dangas GD
    J Am Coll Cardiol; 2015 Apr; 65(13):1298-1310. PubMed ID: 25681754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.